Structure-Based Drug Design Summit - San Diego

Following the success of the Structure-Based Drug Design Summit in Boston, we’re delighted to be bringing this forum to West Coast to unite biopharma’s leaders driving the next era of rational drug design.

Advancements in experimental technologies are delivering atomic and even sub-Ångstrom insights into complex protein structures, while predictive modelling, generative AI, and machine learning are redefining what’s possible in drug design. At the same time, with tightening R AND D budgets the need to derisk early drug discovery programs through more rational drug design or more potent, selective and developable drug candidates is more important than ever.

This is your opportunity to join your peers from across Structural Biology, Medicinal Chemistry, Computational Chemistry, Protein Engineering, Machine Learning and more to stay at the forefront of innovation, benchmark your approaches, and discover how to translate structural insights into better therapies.


URLs:
Website: https://go.evvnt.com/3306337-0?pid=2874
Brochure: https://go.evvnt.com/3306337-3?pid=2874

Category: Conferences | Science, Health & Medicine

Prices:
Drug Developer Pricing (Conference + Workshop Day): USD 3497.00,
Drug Developer Pricing (Conference Only): USD 2599.00,
Academic Pricing (Conference + Workshop Day): USD 2897.00,
Academic Pricing (Conference Only): USD 2199.00,
Service Provider Pricing (Conference + Workshop Day): USD 5197.00,
Service Provider Pricing (Conference Only): USD 3799.00

Speakers: Robert Englmeier, Co-Founder and Chief Executive Officer, CryoCloud, Joao Dias, Senior Director, Eli Lilly, Yunji Davenport, Director, Head of Protein Biochemistry and Structural Biology, Foghorn Therapeutics, Jawahar Sudhamsu, Distinguished Scientist, Structural Biology and Discovery Oncology, Genentech, Eric Lansdon, Executive Director, Structural Biology and Chemistry, Gilead Sciences, Amy Shih, Vice President , Head of Computational Chemistry, Hyku Biosciences, Glen Spraggon, Executive Director - Structure Bioinformatics and Data Science, Novartis, Prakash, Palde Director - Biophysics, High Throughput Screening and Oncology, Pfizer, Suhasini Avvaru, Senior Principal Scientist - Antibody Engineering, Regeneron Pharmaceuticals, Joseph Batchelor, Head of Structural Biology for US Biologics Research, Sanofi, Xianqiang Song, Senior Director - Structural Biology, Structure Therapeutics, Nidhi Arora, Senior Director and Head Computational, Structural and Protein Sciences, Takeda Pharmaceutical, David Fox III, Head of Crystallography, Structural Biology, UCB, Hong Zhou, Professor in the Microbiology, Immunology, and Molecular Genetics, UCLA Health Sciences, Dave Brown, Senior Director Structural Biology and Biophysics, Vertex Pharmaceuticals, Ali Punjani, Chief Executive Officer and Co-Founder, Structura Biotechnology, Brian Sosa-Alvarado, Director, Structural Biology and Platform, MOMA Therapeutics, Sandro Vivona, Director, Discovery Biologics, Protein Sciences, Merck and Co, Weiru Wang, Executive Director - Protein Sciences and Structural Biology, Frontier Medicines